1401937-82-3

Upstream product

• 1401938-22-4 [(16E)-16-(3-carbamoylbenzylidene)-17-oxoestra-1⁽¹⁰⁾,2,4-trien-3-yl]boronic acid 
• 1401938-24-6 [(16E,17β)-16-(3-carbamoylbenzylidene)-17-hydroxyestra-1(10),2,4-trien-3-yl]boronic acid 
• 126534-87-0 3-carboxamidobenzaldehyde 
• 92817-04-4 estrone triflate 

Relevant academic research and scientific papers

Discovery of a non-estrogenic irreversible inhibitor of 17β-Hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m -carbamoylbenzyl)-estradiol derivatives

17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) is thought to play a pivotal role in the progression of estrogen-sensitive breast cancer by transforming estrone (E1) into estradiol (E2). We designed three successive series of E2-derivatives at position C3 of the potent inhibitor 16β-(m-carbamoylbenzyl)-E2 to remove its unwanted estrogenic activity. We report the chemical synthesis and characterization of 20 new E2-derivatives, their evaluation as 17β-HSD1 inhibitors, and their proliferative (estrogenic) activity on estrogen-sensitive cells. The structure-activity relationship study provided a new potent and steroidal nonestrogenic inhibitor of 17β-HSD1 named 3-{[(16β,17β)-3-(2-bromoethyl)-17-hydroxyestra- 1(10),2,4-trien-16-yl]methyl}benzamide (23b). In fact, this compound inhibited the transformation of E1 into E2 by 17β-HSD1 in T-47D cells (IC 50 = 83 nM), did not inhibit 17β-HSD2, 17β-HSD7, 17β-HSD12, and CYP3A4, and did not stimulate the proliferation of estrogen-sensitive MCF-7 cells. We also discussed the results of kinetic and molecular modeling (docking) experiments, suggesting that compound 23b is a competitive and irreversible inhibitor of 17β-HSD1.

INHIBITORS OF 17?-HSD1, 17?-HSD3 AND 17?-HSD10

The present application discloses 17β hydroxy steroid dehydrogenase (17β HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17β HSDl inhibitors include estradiol derivatives with a ni